Australian biotech market watch 28/09/09
Monday, 28 September, 2009
The ASX200 opened sharply lower as expected, and was sitting at 4659 at 11:00am.
Among the pharmaceutical stocks, market heavyweight CSL Limited (ASX:CSL) was down 52c to $33.85
Photoprotective drug manufacturer, Clinuvel Pharmaceuticals (ASX:CUV) slumped nearly 6% to 31.5c after releasing its full year financial results – a 32% drop in revenues and a loss of $15.3M
Cellistis Limited (ASX:CST) fared little better, dropping 12c to $3.25 despite its recent announcement of a record $8.2M annual profit. The Cellistis share price had recently spiked as high as $4.00 and had more than tripled since February.
More positive numbers for Acrux (ASX:ACR) up almost 5% to $1.58 and Chemgenex (ASX:CXS) up almost 4% to 78.5c
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
